{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:07Z","timestamp":1790657767440,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03678-1","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:53:14Z","timestamp":1783569194000},"page":"4492-4506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type\u00a02 Diabetes: A Phase\u00a01 Open-Label, Randomized, Active-Controlled Trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Leohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"10397","key":"3678_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023;402(10397):203\u201334.","journal-title":"The Lancet"},{"issue":"12","key":"3678_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1097\/CM9.0000000000003536","volume":"138","author":"H Zhang","year":"1990","unstructured":"Zhang H, Jia Q, Song P, et al. Incidence, prevalence, and burden of type\u00a02 diabetes in China: trend and projection from 1990 to 2050. Chin Med J (Engl). 1990;138(12):1447\u201355.","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"3678_CR3","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1016\/S2468-2667(24)00250-0","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu Y, Lu J, Li M, et al. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health. 2024;9(12):e1089\u201397.","journal-title":"Lancet Public Health"},{"issue":"23","key":"3678_CR4","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","volume":"391","author":"C Wysham","year":"2024","unstructured":"Wysham C, Bajaj HS, Prato SD, et al. Insulin efsitora versus degludec in type\u00a02 diabetes without previous insulin treatment. N Engl J Med. 2024;391(23):2201\u201311.","journal-title":"N Engl J Med"},{"issue":"3","key":"3678_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/dom.13132","volume":"20","author":"D Russell-Jones","year":"2018","unstructured":"Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3678_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/dom.12886","volume":"19","author":"L Ji","year":"2017","unstructured":"Ji L, Zhang P, Zhu D, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type\u00a02 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19(6):822\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3678_CR7","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00125-024-06158-9","volume":"67","author":"R Trevisan","year":"2024","unstructured":"Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. 2024;67(8):1480\u201392.","journal-title":"Diabetologia"},{"issue":"4","key":"3678_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/dom.14956","volume":"25","author":"T Heise","year":"2023","unstructured":"Heise T, Chien J, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023;25(4):1080\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3678_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.122.001105","volume":"382","author":"JS Moyers","year":"2022","unstructured":"Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. J Pharmacol Exp Ther. 2022;382(3):346\u201355.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"3678_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2337\/dc22-2396","volume":"46","author":"JM Bue-Valleskey","year":"2023","unstructured":"Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type\u00a02 diabetes: a phase\u00a02 randomized control trial. Diabetes Care. 2023;46(5):1060\u20137.","journal-title":"Diabetes Care"},{"issue":"3","key":"3678_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-8587(22)00388-6","volume":"11","author":"J Frias","year":"2023","unstructured":"Frias J, Chien J, Zhang Q, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type\u00a02 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase\u00a02 study. Lancet Diabetes Endocrinol. 2023;11(3):158\u201368.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3678_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2337\/dc22-2395","volume":"46","author":"CM Kazda","year":"2023","unstructured":"Kazda CM, Bue-Valleskey JM, Chien J, et al. Novel once-weekly basal insulin Fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type\u00a01 diabetes. Diabetes Care. 2023;46(5):1052\u20139.","journal-title":"Diabetes Care"},{"issue":"10497","key":"3678_CR13","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","volume":"405","author":"A Philis-Tsimikas","year":"2025","unstructured":"Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type\u00a02 diabetes currently treated with basal insulin (QWINT-3): a phase\u00a03, randomised, non-inferiority trial. Lancet. 2025;405(10497):2279\u201389.","journal-title":"Lancet"},{"issue":"10497","key":"3678_CR14","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, Dahl D, P\u00e9rez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type\u00a02 diabetes treated with basal and prandial insulin (QWINT-4): a phase\u00a03, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290\u2013301.","journal-title":"Lancet"},{"issue":"3","key":"3678_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13300-025-01695-x","volume":"16","author":"R Nasu","year":"2025","unstructured":"Nasu R, Oura T, Ohwaki K, Imori M, Furihata K. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin efsitora alfa in Japanese patients with type\u00a02 diabetes. Diabetes Ther. 2025;16(3):513\u201326.","journal-title":"Diabetes Ther"},{"issue":"1","key":"3678_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/dbi17-0013","volume":"67","author":"C Hu","year":"2017","unstructured":"Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2017;67(1):3\u201311.","journal-title":"Diabetes"},{"issue":"9","key":"3678_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.eprac.2024.06.007","volume":"30","author":"TR Pieber","year":"2024","unstructured":"Pieber TR, Leohr J, Bue-Valleskey JM, et al. Understanding the pharmacokinetics and glucodynamics of once weekly basal insulins to inform dosing principles: an introduction to clinicians. Endocr Pract. 2024;30(9):863\u20139.","journal-title":"Endocr Pract"},{"issue":"10497","key":"3678_CR18","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, Dahl D, P\u00e9rez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type\u00a02 diabetes treated with basal and prandial insulin (QWINT-4): a phase\u00a03, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290\u2013301.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03678-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03678-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03678-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:46Z","timestamp":1790655286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03678-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03678-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yihui wang, Yuan Yuan, and Jennifer K. Leohr are Lilly employees and minor shareholders. Hui Liu, Yuxin Fan, Ming Liu and Yerong Yu have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, Declaration of Helsinki, International Council for Harmonization Good Clinical Practice (ICH-GCP) guidelines, and applicable local regulations. The study protocol and informed consent forms were reviewed and approved by the institutional ethics committees at each participating site. Ethical approval was obtained from (a) Ethics Committee on Clinical Trial, West China Hospital of Sichuan University (No. 37, Chengdu, Sichuan Province, China)\u2014Coordinating Investigator, Yerong Yu; and (b) Ethics Committee, Tianjin Medical University General Hospital (No. 154, Tianjin, China)\u2014Investigator, Ming Liu. All participants provided written informed consent prior to any study procedures. This trial is registered under ClinicalTrials.gov identifier NCT05596747.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}